News and Press Releases
Research | CFTR Modulators | Drug Pipeline Cystic Fibrosis Foundation statement on FDA approval of TRIKAFTA, the first triple combination therapy for the most common CF mutation

This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.  

Oct. 21, 2019 | 3 min read
About the CF Foundation | CFTR Modulators CF Foundation Celebrates FDA Approval of Orkambi as Important Advance for the CF Community

Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation

July 2, 2015 | 5 min read
About the CF Foundation | CFTR Modulators The Cystic Fibrosis Foundation Applauds FDA Approval of Kalydeco™, First Drug to Address the Underlying Cause of Cystic Fibrosis

Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model

Jan. 31, 2012 | 5 min read